Previous 10 | Next 10 |
● In Support of Research for Treating the 4 Million Canadians Who Have Chronic Kidney Disease Today ● CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Fran...
● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) ● CALGARY, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc...
2023-08-04 17:19:06 ET XORTX Therapeutics ( NASDAQ: XRTX ) has named James Fairbairn as its chief financial officer, the company said Friday. Fairbairn will replace Amar Keshri, who left the company effective July 31, 2023. Fa...
CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
2023-06-29 12:19:43 ET In its annual and special meeting of shareholders held on Wednesday, June 28, 2023, XORTX Therapeutics ( NASDAQ: XRTX ) announces appointment James Fairbairn as Interim CFO. Source: Press Release For further details see: XORT...
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTX’s board of directors recommends shareholders vote FOR the election of all director nominees, FOR the appointment of auditors of the en...
CALGARY, Alberta, June 06, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
CALGARY, Alberta, May 24, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease...
2023-05-04 10:04:37 ET XORTX Therapeutics ( NASDAQ: XRTX ) announced a positive outcome of their recent Type D meeting with the U.S. Food and Drug Administration regarding the accelerated approval of XORLO as a treatment for autosomal dominant polycystic kidney disease ((ADPKD). T...
News, Short Squeeze, Breakout and More Instantly...
XORTX Therapeutics Inc. Company Name:
XRTX Stock Symbol:
NASDAQ Market:
XORTX Therapeutics Inc. Website:
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to anno...
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...